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AbsTRACT
Around 40% of all patients undergoing angiography 
are found to have normal coronary arteries or non-
obstructive coronary artery disease (NOCAD). Despite 
the high prevalence, this is a group who rarely receive a 
definitive diagnosis, are frequently labelled and managed 
inappropriately and by and large, continue to remain 
symptomatic. Half of this group will have coronary 
microvascular dysfunction (CMD), associated with a 
higher rate of major adverse cardiovascular events; 
identifying CMD represents a therapeutic target of 
unmet need. As the pressure wire has revolutionised our 
ability to interrogate epicardial coronary disease during 
the time of angiography, measuring flow can similarly 
classify NOCAD during a single procedure. Assessment 
of flow is a function that is already integral to some 
pressure wires and furthermore, the familiarity and usage 
of the combined Doppler and pressure wire is rapidly 
increasing—these are techniques that readily lend 
themselves to the skillset of a practising interventional 
cardiologist. We present a structured algorithm designed 
for cardiologists who frequently encounter NOCAD 
in the catheter laboratory, identifying specific disease 
phenotypes within this heterogeneous population with 
linked therapy. This review paper clearly explains the 
rationale for this algorithm and outlines its applicability 
to routine clinical practice and also, the importance of 
phenotyping for future research. Ultimately, personalised 
therapy could improve outcomes for both patients and 
healthcare providers; while these approaches in turn 
will need robust evaluation to ensure that they improve 
both clinical outcomes and health economic benefits, this 
proposal will provide a framework for future trials and 
evaluations.
CliniCAl ConTexT
The standard of care for investigating stable angina 
in patients with an intermediate-high likelihood 
of coronary artery disease (CAD) is the coronary 
angiogram. In a registry of nearly 400 000 patients 
undergoing invasive coronary angiography, approx-
imately 40% had Non-Obstructive Coronary Artery 
Disease, a diagnosis often referred to as ‘NOCAD’.1 
NOCAD is associated with worse healthcare 
outcomes and higher economical costs than previ-
ously appreciated.2 This umbrella term encom-
passes a broad range of cardiac pathophysiological 
abnormalities, including endothelial dysfunction, 
microvascular remodelling (structural), micro-
vascular and epicardial spasm (functional), vaso-
motor abnormalities and enhanced cardiac pain 
perception in addition to non-cardiac chest pain. 
Demonstrable ischemia with normal coronary 
arteries (INOCA) is a recent term used to describe 
subsets of NOCAD patients, however this neither 
distinguishes aetiology nor involves direct assess-
ment of the microvasculature.3 In 1988, the term 
coronary microvascular dysfunction (CMD) was 
used to refine this heterogeneous group of disorders 
in the sizeable proportion of patients who exhibited 
a functional abnormality in the microcirculation 
when measured directly—with either inadequate 
vasodilator response to pharmacological or pacing 
stimuli or enhanced sensitivity to vasoconstrictive 
stimuli.4 The presence of CMD heralds a worse 
prognosis with an increased risk of major adverse 
cardiovascular events (MACE) in the longer term, 
but also represents a therapeutic target of unmet 
need.5 The severity of myocardial ischemia attribut-
able to microvascular disease is independently asso-
ciated with excess cardiovascular risk and correlates 
well with symptom burden.6 7 Cardiac Syndrome X 
is a historical term used to describe patients with 
angina, angiographically smooth coronary arteries 
and an exercise ECG demonstrating ischaemia. 
Older non-invasive stress testing (exercise ECG, 
stress echocardiography or nuclear imaging) had 
low sensitivity (41%) and specificity (57%) at iden-
tifying patients characterised by the invasive gold 
standard.8 Given that CMD may be associated with 
perfusion abnormalities confined to the subendo-
cardial layer of myocardium, modalities with higher 
spatial resolution, such as cardiac MRI may allow 
more accurate detection of this condition.9 
Conventional stress testing can overlook coro-
nary vasospasm, a functional disorder of the 
coronary circulation, typically triggered by cold 
air or emotional stress rather than physical exer-
tion (often resulting in a true ‘negative’ stress test) 
and is a distinct diagnosis to CMD. Physicians 
aware of the poor accuracy of non-invasive tests, 
often wrongly dismiss CMD as a cause of symp-
toms while conversely, if microvascular angina is 
presumed without verification, empirical treatment 
with angina medication may result in inappropriate 
treatment of patients with a non-cardiac problem. 
Both CMD and coronary vasospasm would benefit 
from clearer diagnostic pathways.
Diagnosis and treatment in current practice
Traditional atherosclerotic risk factors and ‘typi-
cality’ of angina are poor predictors of CMD, 
necessitating objective tests to establish a clinical 
diagnosis; however, tests of coronary microvascular 
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Figure 1 Compartmental model of the coronary epicardial and 
microcirculation and how to interrogate the respective components. 
CFR, coronary flow reserve; FFR, fractional flow reserve; hMR, 
hyperaemic microvascular resistance; IMR, index of microcirculatory 
resistance.
function are rarely used in clinical practice.10 Patients are frus-
trated by a lack of clarity and effective management for this 
problem, often being subject to repeated invasive coronary 
angiography when symptoms persist, with associated health 
and economic burden.11 The European Society of Cardiology 
(ESC) guidelines suggest empirical use of traditional antianginal 
therapies for symptom relief in NOCAD along with aspirin, 3 
-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) 
and ACE inhibitors for secondary prevention.12 To date, very few 
randomised controlled trials have been performed in patients 
with confirmed CMD and these gaps in evidence are reflected in 
the relatively soft and contradictory recommendations provided 
by international guidelines.
The ability to physiologically characterise CAD at the time of 
angiography by pressure-wire assessment has revolutionised the 
interventional cardiology field.13 Advances in guidewire tech-
nology now also enable the immediate assessment of the coronary 
microcirculation to provide clarity into the NOCAD diagnosis. 
The Coronary Microvascular Angina randomised-controlled 
trial (CorMicA) recently demonstrated that a tiered approach 
for assessment of microvascular or vasospastic angina in patients 
with NOCAD is superior to usual care.14 Contemporary guide-
lines from the Coronary Vasomotion Disorders International 
Study (COVADIS) Group mandate invasive coronary reac-
tivity testing to establish a definitive diagnosis of microvascular 
angina secondary to CMD or coronary vasospasm.15 CMD can 
be identified during a single cardiac catheterisation procedure, 
overcoming issues of specificity and sensitivity associated with 
non-invasive ischaemia tests. Coronary reactivity testing has a 
high diagnostic yield of identifying CMD and vasospasm (60%) 
with small additional procedural risks (up to 0.7%), carrying 
a IIb indication on ESC guidelines for investigating refractory 
angina.12 16 17 Other authors have proposed diagnostic algorithms 
to stratify NOCAD; however, our aim is to further simplify this 
message.18
In this review, we propose an approach that involves routine 
assessment of microvascular function in all patients shown to 
have NOCAD, aimed at establishing diagnoses in the majority 
and allowing standardised classification of phenotype. The latter 
will provide the foundation for collating data for research and 
international audit purposes and will ultimately act as the basis 
for stratified medicine in this large group of patients, who are 
poorly served by current clinical practice. We review the evidence 
underlying this proposal and finally provide a simple algorithm 
that could be implemented in most cardiovascular centres that 
manage such patients.
The CMD and CAD continuum: insights from recent trials
For simplicity, the coronary circulation is often described using a 
two-compartment model: the epicardial arteries and the micro-
circulation (figure 1). Both CMD and CAD often coexist and it 
is only for simplicity that they are considered as dichotomous 
entities when classifying patients in the clinical setting. Several 
recent randomised controlled trials of patients with CAD have 
encompassed patients with NOCAD, highlighting the relative 
frequency of this condition, demanding therapies distinct from 
CAD (table 1). A binary approach restricted to coronary angi-
ography without appreciating the microcirculation may account 
for equivocal results demonstrated in some studies looking at 
prognostic and symptomatic benefits of percutaneous coronary 
intervention (PCI). There is growing interest in the comprehen-
sive assessment of epicardial stenoses with emerging evidence 
that the microvascular component is a greater determinant of 
prognosis.19 This is currently being investigated in more detail 
by the randomised controlled trial DEFINE Flow, where only 
patients with both flow-limiting CAD (FFR≤0.80) and impaired 
vasodilator reserve (CFR<2.0) undergo PCI.
Comprehensive assessment of noCAD in the cardiac 
catheterisation laboratory
A patient presenting for coronary angiography can be charac-
terised beyond a NOCAD diagnosis during the same procedure 
(figure 2).
Coronary angiography and physiological assessment to rule in/rule 
out obstructive CAD
Initial anatomical assessment of the coronary arteries may iden-
tify the presence of critical obstructive epicardial disease, or 
in the case of angiographically smooth unobstructed vessels, 
allow this to be definitively excluded. Physiological evaluation 
of CAD is superior to visual angiographic appraisal at detecting 
disease capable of causing ischaemia and using these techniques 
to guide revascularisation decisions has been shown to produce 
superior outcomes.20 The pressure-wire derived index of frac-
tional flow reserve (FFR) has prognostic utility in the stable 
CAD population while also representing a cost-effective health-
care economical strategy.21 Resting and submaximal hyperaemic 
indices are emerging alternative options to FFR.22 Equivocal 
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Table 1 Insights from recent randomised controlled trials specific to patients with NOCAD and CMD.
Trial, journal and year Patients with noCAD (n) Pertinent results in patients with noCAD Take home messages for noCAD
FAME-2, NEJM, 201213 332/1220 (27%) of patients had an 
FFR >0.80
 ► Similar CCS angina class compared with FFR <0.80.
 ► Similar levels of silent ischaemia compared with FFR <0.80.
 ► MACE rate of 9% in 2 years.
 ► Patients with NOCAD have similar symptom burden to 
patients with CAD.
 ► Patients with NOCAD have a high MACE rate.
PROMISE, NEJM, 201536 4477/4996 (90%) of patients in the CTCA 
group had a ‘negative’ result
 ► 89% of patients had typical or atypical angina in both 
groups.
 ► Only 10% of patients in the CTCA group had angina 
attributable to CAD.
 ► A large proportion of anginal symptoms are attributable 
to NOCAD in patients with an intermediate PTP of CAD.
SCOT-HEART, Lancet, 201537 1326/1778 (75%) in the CTCA groups had 
anatomical NOCAD
 ► CTCA-guided therapy resulted in a reduced diagnosis of 
angina due to CAD, prompting alteration of therapy in this 
group, and deterioration in QoL and symptoms.
 ► Patients in the CTCA group with a change in diagnosis, 
either confirming obstructive CAD or excluding CAD 
had the greatest improvement in symptoms, while those 
with non-obstructive CAD had the least improvement in 
symptoms.
 ► In a population with high predicted 10-year CHD risk, 
NOCAD is common.
 ► Defining NOCAD anatomically (instead of with FFR) 
may explain the poorer outcomes in the non-obstructive 
CAD group.
 ► Inappropriate cessation of antianginal therapy in 
patients with NOCAD with CMD may have attenuated 
symptom improvement derived by identifying CAD and 
revascularisation leading to symptom neutrality when 
adopting a CTCA-guided approach.
CE-MARC 2, JAMA, 2016 38 139/265 (52%) of patients who underwent 
angiography had NOCAD
 ► All 1202 patients had angina with 401 (33%) having 
typical angina.
 ► A minority of patients had a positive non-invasive test 
(12.4% in the CMR group, 18.2% in the MPS group and 
13.4% in the NICE guideline group).
 ► Adhering to NICE guidelines results in a frequent 
diagnosis of NOCAD.
 ► The rate of ‘unnecessary angiography’ was nearly double 
in women, compared with the rate in men.
ORBITA, Lancet, 201739 57/200 (29%) of patients had an FFR >0.80  ► In a sham-placebo trial, PCI was found to be equivalent to 
OMT in providing symptom relief.
 ► Patients with angina and FFR >0.80 also underwent PCI 
and may have diluted effects between the groups.
 ► NOCAD is common among lesions judged to be visually 
severe.
 ► Differences in microvascular physiology is postulated to 
have contributed to inconsistent benefits of PCI.
ISCHAEMIA and CIAO-
ISCHAEMIA substudy, tba40
5179 patients with moderate ischaemic 
burden have been randomised to an 
invasive approach versus OMT (ISCHAEMIA 
trial)
 ► A proportion of patients with moderate-to-severe 
ischaemia on stress testing have NOCAD (enough to justify 
forming the CIAO-ISCHAEMIA substudy).
INOCA is an increasingly recognised entity that warrants 
specific management.
CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; CFR, coronary flow reserve; CMR, cardiovascular magnetic resonance; CTCA, CT coronary angiography; FFR, fractional flow reserve; INOCA, ischaemia 
with no obstructive coronary disease; MACE, major adverse cardiovascular events; MPS, myocardial perfusion scintigraphy; NICE, National Institute for Health and Clinical Excellence; NOCAD, non-obstructive coronary 
artery disease; OMT, optimal medical therapy; PCI, percutaneous coronary intervention; PTP, pretest probability. 
epicardial artery stenoses (diameter stenosis from 40% to 90%) 
should be interrogated in line with contemporary practice guide-
lines, all physiological techniques being superior to anatomical 
assessment alone. The presence of non-obstructive atheroscle-
rotic disease heralds a poorer prognosis among NOCAD and 
should be managed with secondary preventative therapy.11 
Plaque rupture of non-obstructive atheromatous disease can be a 
source of MACE in addition to the presence of ischaemia within 
intramyocardial vessels. The absence of flow-limiting epicardial 
disease, or NOCAD, should then prompt a stratified approach 
to identify an ischaemic substrate for the presenting symptoms.
Assessment of coronary flow reserve (endothelium-independent 
microvascular function)
In the absence of physiologically flow-limiting epicardial disease, 
reduced coronary flow reserve (CFR) indicates the presence of 
CMD. CFR is defined as the ratio of maximal blood flow during 
hyperaemia, to resting blood flow and is the clinical reference 
standard for quantitative assessment of microvascular vasodil-
atory reserve; in the absence of epicardial coronary disease, 
values below 2.0 are abnormal while values above 2.5 indicate 
normal microvascular function. Absolute coronary flow is diffi-
cult to measure in a clinical setting but Doppler-based techniques 
are used to measure coronary flow velocity, which is used as a 
surrogate of flow when calculating CFR, as it has been shown 
that there is negligible variation in epicardial vessel diameter in 
response to adenosine. Thermodilution techniques can also be 
used; as flow is inversely proportional to transit time of a cold 
bolus of saline, CFR can be defined as the ratio of mean transit 
time at baseline and hyperaemia. Given that CFR can only be 
used to quantify microvascular function in the absence of epicar-
dial conduit artery disease, newer parameters have recently 
been evaluated to directly measure microvascular resistance 
(MR). MR is defined as the ratio between myocardial perfusion 
pressure (which approximates to distal coronary pressure (Pd)) 
and flow; when flow is estimated by Doppler flow velocity the 
resulting index is called hyperaemic microvascular resistance 
(hMR=Pd/APV, where APV is average peak velocity) and when 
flow is estimated by thermodilution, it is called index of micro-
vascular resistance (IMR=Pd×Tm, where Tm is mean transit 
time). In the context of NOCAD, hMR >2.4 mm.Hg/cm.s or 
IMR >25 units suggests underlying microvascular dysfunction 
and correlates with symptom burden.7 23 Reduced CFR is often 
associated with atherosclerotic disease not immediately apparent 
on angiographic appearance, assessment of MR may delineate 
between diffuse epicardial and microvascular pathology.24 
Patients with a normal CFR but increased hMR/IMR represent 
a distinct group of patients who may also benefit from therapy 
for CMD.14
FFR, CFR and MR can now be calculated using a single 0.014-
inch coronary wire, either a dual pressure and Doppler sensor-
tipped guidewire (ComboWire Guidewire; Philips Volcano, 
San Diego, California, USA) or a pressure wire with tempera-
ture thermistor on the distal shaft and tip (Abbot, Santa Clara, 
California, USA). While Doppler has the temporal resolution to 
identify changes in coronary blood flow during the cardiac cycle, 
use is limited by operator expertise and a steep learning curve. 
Thermodilution has demonstrable comparability to Doppler 
but is not identical in all scenarios.25 Where adenosine-medi-
ated (endothelial-independent) vasodilatation is unimpaired, 
the operator should consider testing for endothelium-dependent 
microvascular dysfunction function.
Assessment of endothelium-dependant microvascular function
Endothelial dysfunction precedes atherosclerosis and often 
coexists with abnormalities in microvascular smooth muscle 
dysfunction. In coronary arteries with normal endothelium, 
intracoronary acetylcholine (ACh) dilates the epicardial and 
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Figure 2 Comprehensive assessment of NOCAD during the time 
of angiography. *Evaluation of atheromatous disease can be carried 
out using resting or submaximal hyperaemic indices based on local 
practice. §Patients with visible atheroma should be commenced on 
secondary preventative therapy regardless of final diagnosis. The 
white area describes tests available on an ad hoc basis in all catheter 
laboratories, whereas the grey shaded area describes acetylcholine 
testing that can currently only be performed on a named-patient basis 
clinically, or within the context of dedicated research protocols, limiting 
its widespread ad hoc use. CAD, coronary artery disease; CFR,  coronary 
flow reserve; CMD,  coronary microvascular dysfunction;  FFR,  fractional 
flow reserve; NOCAD, non-obstructive coronary artery disease.
microvascular circulation, increasing CBF. In the presence of 
healthy endothelium, ACh causes vasodilation by generating 
nitric oxide that acts on the surrounding vascular smooth muscle. 
Depending on the integrity of the endothelium and reactivity 
of the surrounding smooth, ACh can result in either vasodila-
tation or vasoconstriction. ACh is administered as a slow infu-
sion over 2 min, via the coronary guiding catheter (to prevent 
systemic effects), starting with an initial low dose of 0.18 µg/min 
followed by a high dose at 18 µg/min.16 A below 50% increase 
in CBF from baseline or ischaemic ECG changes and pain in the 
absence of epicardial vasoconstriction (>90% diameter reduc-
tion) is diagnostic of microvascular endothelial dysfunction and 
is associated with a poorer prognosis.26 If no abnormalities are 
detected using these doses of ACh, higher ‘provocation’ doses 
can be used to unmask a diagnosis of coronary vasospasm.
Provocation testing for coronary vasospasm
The reference method for provocative spasm testing involves 
intracoronary administration of a provocative stimulus during 
invasive coronary angiography with the monitoring of patient 
symptoms, ECG and angiographic documentation of coro-
nary artery spasm. A positive provocation test as defined by 
COVADIS entails: (1) reproduction of the usual chest pain, 
(2) ischaemic ECG changes and (3) >90% vasoconstriction on 
quantitative coronary angiography.27 Microvascular spasm is 
diagnosed where chest pain and ischaemic ECG changes occur 
in the absence of epicardial artery constriction.17 High dose ACh 
provocation is commonly used to induce abnormal coronary 
vasospasm, where incremental bolus doses of 20, 50 and 100 µg 
are injected into the left coronary artery at 5 min intervals. If 
negative, this is repeated in the right coronary artery in a similar 
manner, at doses of 20 and 50 µg. Liberal intracoronary glyc-
eryl trinitrate usually alleviates ACh-induced vasospasm.
non-invasive diagnosis of CMD
The wider adoption of anatomical imaging with CT coronary 
angiography (CTCA) as a first-line diagnostic test for the assess-
ment of stable chest pain may increase the diagnosis of NOCAD. 
The higher sensitivity and spatial resolution afforded by perfu-
sion cardiac MRI can be used to rule-out those unlikely to have 
CMD. Novel gadolinium-free mapping techniques may have 
a role upstream of anatomical imaging assessment, of distin-
guishing CAD, CMD and non-ischaemic chest pain and will 
need to be studied further.28 While these hybrid and novel 
imaging approaches greatly improve the heterogeneity conferred 
by a NOCAD diagnosis by assessing for CMD, this approach is 
currently unable to identify coronary vasospasm.
Therapeutic interventions in CMD
Robust clinical trial evidence for the treatment of CMD 
is lacking and the optimal management strategies in these 
patients remains undefined. The evidence base largely comes 
from small diagnostic studies, which have sometimes yielded 
conflicting results and have often used variable inclusion 
criteria, differing diagnostic test thresholds and dissimilar 
endpoints. Most therapeutic trials have involved patient 
cohorts without a precise diagnosis of CMD, but instead have 
been classified as Syndrome X or INOCA (table 2). Thera-
peutic agents in CMD may be considered symptom-modifying 
or disease-modifying agents. In current practice, antianginal 
therapy and secondary prevention tends to be empirical and 
follows a similar paradigm to the evidence-based therapies for 
obstructive epicardial CAD. Non-pharmacological therapies 
such as exercise training in cardiac rehabilitation programmes, 
improve resting diastolic blood pressure and exercise capacity 
in patients with CMD, while cognitive behavioural therapy and 
spinal cord stimulation may help in subsets of patients with 
high autonomic tone or abnormal nociception, respectively.29 
The need for further therapeutic options is highlighted by the 
approximately one-third of patients with NOCAD who have 
refractory angina.30
Disease-modifying agents in CMD
The current ESC guidelines recommend treatment with aspirin 
and statin (class I indication), and consideration of ACE inhib-
itors (IIb indication) for NOCAD.12 Intracoronary ultrasound 
of patients with NOCAD suggest a high prevalence of epicar-
dial atherosclerosis; aspirin is recommended by extrapolation 
of CAD studies.31 There is evidence from small randomised 
trials that treatment with ACE inhibitors and statins may 
be beneficial in CMD.32–35 Statin therapy reduces cardio-
vascular risk via low-density lipoprotein reduction but has 
several pleiotropic effects including improvements in vascular 
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Table 2 Therapeutic studies in patients with syndrome X or INOCA and those with confirmed CMD
Drug class syndrome x/inoCA population CMD population
First-line antianginal agents
  Beta blocker Randomised double-blind crossover studies—reduced angina, less ST 
depression episodes, improved markers of endothelial function41
Not tested in this population
  Calcium channel blockers Reduced angina, increased exercise time42 Only single dose of intravenous diltiazem tested did not improve 
CFR immediately43
  Nitrates Reduced ischaemic threshold to exercise or rapid pacing44 Not tested in this population
Second-line antianginal agents
  Nicorandil Not tested Increased ischaemic threshold (using CFR <3.0 as CMD 
inclusion)45
  Ranolazine Contradictory, improved or unchanged symptoms46 Improved symptoms and reduced coronary microvascular 
resistance measured invasively (using CFR<2.5 or IMR>20 U as 
CMD inclusion)47
Disease-modifying agents
  ACE inhibitors Increased exercise duration, ischaemic threshold, endothelial function and 
CFR48
Improved CFR at 16 weeks (using CFR<3.0 as CMD inclusion)49
  Statins Improved symptoms, exercise tolerance and endothelial function50 Improved coronary ACh CFR after 6 months treatment (using 
ACh CFR <1.5 as CMD inclusion)32
Green text emphasises improvement with medication and red text emphasises deterioration with medication.
CFR, coronary flow reserve; CMD, coronary microvascular dysfunction; INOCA,  ischaemia with no obstructive coronary arteries. 
inflammation and enhanced endothelial function. Angiotensin 
II is a potent vasoconstrictor and may modulate coronary 
microvascular tone directly and indirectly via left ventricular 
effects on cardiac–coronary coupling.
Antianginal therapies for CMD
While the evidence base for antianginal therapy in CMD is less 
mature than for other conditions, notably obstructive CAD, 
we believe there is sufficient evidence, as outlined in contem-
porary guidelines, to make informed, personalised decisions 
for patients with ongoing symptoms and demonstrable isch-
aemia. Non-dihydropyridine calcium channel blockers are 
efficacious in both CMD and coronary vasospasm and there-
fore should be used first line for CMD where coronary vaso-
spasm has not been ruled out. Beta-blockers can be beneficial 
in CMD but may potentiate coronary vasospasm due to unop-
posed α-receptor agonism, meaning they should be used as 
first-line therapy for CMD provided coronary vasospasm has 
been ruled out by vasoreactivity testing with acetylcholine. 
Nicorandil and ranolazine should be used as second-line and 
third-line therapies for CMD if symptoms persist.12 14
Therapies for coronary vasospasm
The clinical manifestations of coronary vasospasm include 
sudden cardiac death, myocardial infarction and syncope, 
with therapies such as calcium channel blockers and statins 
shown to improve this adverse prognosis.33 Calcium channel 
blocker are highly efficacious for treating coronary vasospasm 
with long-acting nitrates being suitable second-line agents, 
while statins augment the effect of both and should also be 
considered a first-line agent.34 Novel therapeutics are being 
investigated for coronary vasospasm and these studies give 
an indication of the paradigm shift in therapeutics that needs 
to be considered for patients with NOCAD. Endothelin is a 
potent vasoconstrictor and abnormalities in the endothelin 
pathway are associated with coronary microvascular dysfunc-
tion.35 Endothelin receptor antagonist therapy has been asso-
ciated with enhanced coronary endothelial function in patients 
with angiographically unobstructed coronaries and this may 
represent a targeted therapeutic agent for patients with epicar-
dial and microvascular endothelial dysfunction.
Future research in noCAD and CMD
Future clinical trial designs of existing and novel therapeutic 
agents in patients with NOCAD should enrol patients with 
symptoms and defined phenotypes. The stratified medicine 
approach is aimed at identifying specific disease phenotypes 
within a heterogeneous population with linked therapy; better 
diagnosis will yield better disease-specific treatments that will 
improve the outcomes of all patients with NOCAD. CorMicA 
has demonstrated that ad hoc use of coronary function tests in 
appropriately selected patients during routine clinical practice 
leads to health and economic benefits.14 While vasodilators are 
central to diagnosing CMD in clinical practice, patients develop 
symptoms during physical exercise and mental stress, physio-
logically distinct states to pharmacological hyperaemia. Mech-
anistic studies directly measuring Doppler–derived CBF and 
cardiac–coronary coupling, look to unravel whether patients 
with CMD display maladaptation during physical exercise. 
Larger registries combined with enhanced understanding of 
the underlying pathophysiology will provide insight into CMD 
subtypes and in the future may yield better targeted therapy. 
Ultimately, large adequately powered health outcomes trials 
are needed to determine whether hard morbidity and mortality 
endpoints may be improved by targeted therapy.
ConClusion
Contemporary practice dictates that diagnostic clarity is 
needed beyond an all-encompassing NOCAD diagnosis to 
enable targeted therapy and personalised medicine. Clin-
ically available guidewires provide an opportunity to better 
identify the ischaemic substrate at the time of angiography, by 
measurement of FFR and CFR that could influence the clinical 
management of a subset of patients with NOCAD. The supe-
rior classification of NOCAD phenotypes will also facilitate 
mechanistic trials to yield more informative results compared 
with those that previously recruited heterogonous patient 
groups and could serve as a platform for much needed future 
therapies for patients with INOCA. The ultimate goal would 
be to improve our management of this increasingly recognised 
and poorly managed condition, while improving resource allo-
cation during a time of healthcare austerity.
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